Azathioprine
- PDF / 169,214 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 21 Downloads / 171 Views
1 S
Hepatotoxicity: case report An approximately 59-year-old man developed hepatotoxicity during treatment with azathioprine for pancolonic ulcerative colitis. The man was diagnosed with compensated alcoholic liver cirrhosis in 2012 and pancolonic ulcerative colitis in 2017. Thereafter, he had a 3 severe flares of ulcerative colitis, which were treated with unspecified corticosteroids as induction and mesalazine [5-ASA] as maintenance therapy. In 2018, he was started on azathioprine treatment [route and dosage not stated]. Two weeks after the initiation of treatment, he developed hepatotoxicity with transaminases more than 3 times the upper limit of normal. The man’s azathioprine treatment was discontinued. In 2019, at the age of 60, he presented with a new onset of severe ulcerative colitis flare (Mayo score 9). Therefore, he was initiated on infliximab [Zessly]. Six weeks later, clinical and biological remission was achieved with resolution of hepatotoxicity. Mihai C, et al. Anti-tnf treatment (zessly) in a patient with ulcerative colitis and liver cirrhosis-case presentation. Journal of Gastrointestinal and Liver Diseases 28 (Suppl. 3): 803497609 13 abstr. 28, Sep 2019 [abstract]
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
